Comparing of Kala Pharmaceuticals Inc. (KALA) and Surface Oncology Inc. (NASDAQ:SURF)

Since Kala Pharmaceuticals Inc. (NASDAQ:KALA) and Surface Oncology Inc. (NASDAQ:SURF) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kala Pharmaceuticals Inc. N/A 0.00 66.74M -3.30 0.00
Surface Oncology Inc. 59.42M 2.20 6.61M -0.54 0.00

Table 1 highlights Kala Pharmaceuticals Inc. and Surface Oncology Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Kala Pharmaceuticals Inc. 0.00% -72.1% -52.7%
Surface Oncology Inc. -11.12% 63.7% 15.3%


The Current Ratio of Kala Pharmaceuticals Inc. is 6.3 while its Quick Ratio stands at 6.3. The Current Ratio of rival Surface Oncology Inc. is 6.4 and its Quick Ratio is has 6.4. Surface Oncology Inc. is better equipped to clear short and long-term obligations than Kala Pharmaceuticals Inc.

Analyst Ratings

The next table highlights the given recommendations and ratings for Kala Pharmaceuticals Inc. and Surface Oncology Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Kala Pharmaceuticals Inc. 0 0 1 3.00
Surface Oncology Inc. 0 0 0 0.00

The upside potential is 74.62% for Kala Pharmaceuticals Inc. with average price target of $15.

Insider and Institutional Ownership

Roughly 81.6% of Kala Pharmaceuticals Inc. shares are held by institutional investors while 60.3% of Surface Oncology Inc. are owned by institutional investors. Insiders held 3.2% of Kala Pharmaceuticals Inc. shares. Competitively, Surface Oncology Inc. has 0.3% of it’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Kala Pharmaceuticals Inc. -2.95% 54.43% 34.7% -33.95% -41.94% 74.64%
Surface Oncology Inc. -2.58% -27.65% -47.41% -54.24% 0% -1.89%

For the past year Kala Pharmaceuticals Inc. had bullish trend while Surface Oncology Inc. had bearish trend.


Surface Oncology Inc. beats Kala Pharmaceuticals Inc. on 7 of the 10 factors.

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The companyÂ’s product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.